{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:44:44Z","timestamp":1788997484138,"version":"build-2803163510"},"reference-count":70,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Introduction: The proportion of elderly patients with IBD is steadily increasing due to the aging population and improved survival. Patients in this age group present specificities in diagnosis and treatment, particularly regarding the use of biological agents, where immunosenescence, multimorbidity, and polypharmacy affect the precise assessment of benefit and risk. Aim: This systematic review, which was conducted in accordance with the PRISMA 2020 statement, aims to synthesize available data on the epidemiology, clinical characteristics, and therapeutic management of IBD in the elderly, with emphasis on the most recent data and practical guidelines for the use of biological therapies. Methods: A systematic search of PubMed, Scopus, and Embase was conducted. A total of 40 studies were included, comprising 5 randomized controlled trials, 15 prospective cohort studies, and 20 retrospective observational studies. Eligible studies included randomized controlled trials, observational cohort studies, and population-based analyses. Given substantial clinical and methodological heterogeneity, findings were synthesized narratively. Data on demographics, disease phenotype, comorbidities, and treatment outcomes were extracted and analyzed. In addition, a narrative synthesis of major randomized trials of biologic therapies, recent guidelines, and data from prospective studies and patient registries was performed with a focus on safety and real-world outcomes in the elderly. Risk of bias was assessed using the Newcastle\u2013Ottawa Scale (NOS) and the Cochrane Risk of Bias tool. Results: The majority of included studies (85%) were found to have a low to moderate risk of bias, providing a reliable basis for the synthesis. Data show an increasing incidence of IBD in the elderly, often with a milder clinical course and a higher ratio of UC to CD. Multimorbidity and polypharmacy are significant challenges that increase the risk of adverse events. Although classic therapies remain effective, in many cases, a lower threshold is required to initiate advanced therapies, such as biologic agents. Anti-tumor necrosis factor (anti-TNF) agents, as well as biologics with alternative mechanisms of action such as vedolizumab (\u03b14\u03b27 integrin antagonist) and ustekinumab (interleukin-12\/23 inhibitor), represent key therapeutic options in elderly patients with IBD. These biologic factors have efficacy comparable to that in younger patients and are considered attractive options due to reduced systemic immunosuppression and favorable safety profiles. JAK inhibitors are a practical option but are associated with an increased thromboembolic risk and require careful patient selection. Older age is associated with higher absolute rates of serious infections, hospitalizations, and, in some series, mortality. Individualized decision-making, including frailty assessment, vaccination coverage, infection control, and dose adjustments based on renal and hepatic function, is essential for optimal care. Conclusions: IBD in the elderly is a distinct clinical entity with unique challenges in diagnosis and management. A multidisciplinary approach and individualized treatment strategies are essential to ensure the balance between disease control and minimizing the risks associated with comorbidity and polypharmacy. Further research, including specifically designed clinical trials, is needed to optimize treatment and outcomes in this unique patient group.<\/jats:p>","DOI":"10.3390\/jpm16020059","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T12:41:16Z","timestamp":1769431276000},"page":"59","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Challenges and Treatment Strategies in Elderly Patients with Inflammatory Bowel Disease: A Systematic Review and Narrative Synthesis"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9115-232X","authenticated-orcid":false,"given":"John K.","family":"Triantafillidis","sequence":"first","affiliation":[{"name":"IBD Unit, \u201cMETROPOLITAN GENERAL\u201d Hospital, 264 Mesogeion Avenue, 15562 Athens, Greece"},{"name":"Hellenic Society of Gastrointestinal Oncology, 354, Iera Odos Str., 12461 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Malgarinos","sequence":"additional","affiliation":[{"name":"IBD Unit, \u201cMETROPOLITAN GENERAL\u201d Hospital, 264 Mesogeion Avenue, 15562 Athens, Greece"},{"name":"Hellenic Society of Gastrointestinal Oncology, 354, Iera Odos Str., 12461 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Kontrarou","sequence":"additional","affiliation":[{"name":"IBD Unit, \u201cMETROPOLITAN GENERAL\u201d Hospital, 264 Mesogeion Avenue, 15562 Athens, Greece"},{"name":"Hellenic Society of Gastrointestinal Oncology, 354, Iera Odos Str., 12461 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8132-2425","authenticated-orcid":false,"given":"Emmanouil","family":"Kritsotakis","sequence":"additional","affiliation":[{"name":"2nd Department of Surgery, Aretaieion University Hospital, School of Medicine, University of Athens, 76 Vas. Sophias Av., 11528 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Polydorou","sequence":"additional","affiliation":[{"name":"School of Medicine, European University Cyprus, 6 Diogenous St. Egkomi, 1516 Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Pantos","sequence":"additional","affiliation":[{"name":"Centre for Human Reproduction, Genesis Athens Clinic, 14-16, 15232 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Sfakianoudis","sequence":"additional","affiliation":[{"name":"Centre for Human Reproduction, Genesis Athens Clinic, 14-16, 15232 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3224-5646","authenticated-orcid":false,"given":"Agni","family":"Pantou","sequence":"additional","affiliation":[{"name":"Centre for Human Reproduction, Genesis Athens Clinic, 14-16, 15232 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Karandreas","sequence":"additional","affiliation":[{"name":"School of Medicine, European University Cyprus, 6 Diogenous St. Egkomi, 1516 Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manousos M.","family":"Konstandoulakis","sequence":"additional","affiliation":[{"name":"Hellenic Society of Gastrointestinal Oncology, 354, Iera Odos Str., 12461 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolos E.","family":"Papalois","sequence":"additional","affiliation":[{"name":"Hellenic Society of Gastrointestinal Oncology, 354, Iera Odos Str., 12461 Athens, Greece"},{"name":"2nd Department of Surgery, Aretaieion University Hospital, School of Medicine, University of Athens, 76 Vas. Sophias Av., 11528 Athens, Greece"},{"name":"School of Medicine, European University Cyprus, 6 Diogenous St. Egkomi, 1516 Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.23736\/S2724-5985.21.02888-6","article-title":"Histology of IBD and related colitides in the elderly","volume":"70","author":"Leoncini","year":"2024","journal-title":"Minerva Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"jjaf003","DOI":"10.1093\/ecco-jcc\/jjaf003","article-title":"Inflammatory bowel diseases in the elderly population: Epidemiology, long-term disease course, surgery rates, and biological use-data from the Veszprem county cohort between 1977 and 2020","volume":"19","author":"Angyal","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s005350170096","article-title":"Ulcerative colitis in the elderly: Clinical patterns and outcome in 51 Greek patients","volume":"36","author":"Triantafillidis","year":"2001","journal-title":"J. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1590-8658(00)80007-9","article-title":"Crohn\u2019s disease in the elderly: Clinical features and long-term outcome of 19 Greek patients","volume":"32","author":"Triantafillidis","year":"2000","journal-title":"Dig. Liver Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/ueg2.70092","article-title":"Elderly-Onset Inflammatory Bowel Disease Has Distinct Disease Characteristics and Treatment Patterns","volume":"13","author":"Granot","year":"2025","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"103708","DOI":"10.1016\/j.autrev.2024.103708","article-title":"Burden of inflammatory bowel disease among elderly, 1990\u20132019: A systematic analysis based on the global burden of disease study 2019","volume":"24","author":"Chen","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1479928","DOI":"10.3389\/fragi.2024.1479928","article-title":"Global burden of inflammatory bowel disease in the elderly: Trends from 1990 to 2021 and projections to 2051","volume":"5","author":"Liu","year":"2024","journal-title":"Front. Aging"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00384-024-04711-x","article-title":"Global, regional, and national burden of inflammatory bowel disease, 1990-2021: Insights from the global burden of disease 2021","volume":"39","author":"Lin","year":"2024","journal-title":"Int. J. Color. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"675","DOI":"10.14309\/ajg.0000000000003143","article-title":"Disproportionately Increasing Incidence of Inflammatory Bowel Disease in Female Patients and the Elderly: An Update Analysis from the Global Burden of Disease Study 2021","volume":"120","author":"Danpanichkul","year":"2025","journal-title":"Am. J. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1007\/s10620-025-08976-2","article-title":"Older Adults with Inflammatory Bowel Disease Epidemiology in the United States: 2000\u20132021","volume":"70","author":"Danpanichkul","year":"2025","journal-title":"Dig. Dis. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/MOG.0000000000001126","article-title":"The management of small bowel Crohn\u2019s disease in older age","volume":"41","author":"Shakweh","year":"2025","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1093\/ibd\/izae184","article-title":"Mortality Trends in Inflammatory Bowel Disease by Age, Sex, and Race in the United States from 1999 to 2020","volume":"31","author":"Aziz","year":"2025","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"102752","DOI":"10.1016\/j.arr.2025.102752","article-title":"The role of the three major intestinal barriers in ulcerative colitis in the elderly","volume":"108","author":"Fu","year":"2025","journal-title":"Ageing Res. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/apt.17543","article-title":"Editorial: Elderly onset inflammatory bowel disease - clues from the largest population-based cohort study","volume":"58","author":"Estevinho","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cger.2020.08.013","article-title":"Inflammatory Bowel Disease in the Older Adult","volume":"37","author":"Waljee","year":"2021","journal-title":"Clin. Geriatr. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"212","DOI":"10.4103\/sjg.sjg_503_22","article-title":"Inflammatory bowel disease in the elderly: A focus on disease characteristics and treatment patterns","volume":"29","author":"Mosli","year":"2023","journal-title":"Saudi J. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.amjms.2024.12.010","article-title":"Meta analysis of the influencing factors of sarcopenia in patients with Crohn\u2019s disease","volume":"369","author":"Yu","year":"2025","journal-title":"Am. J. Med. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.23736\/S2724-5985.21.02886-2","article-title":"Fatigue, sarcopenia, and frailty in older adults with inflammatory bowel disease","volume":"70","author":"Bellone","year":"2024","journal-title":"Minerva Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/apt.17932","article-title":"Impact of inflammatory bowel disease on the risk of acute coronary syndrome: A Swedish Nationwide Cohort Study","volume":"59","author":"Eriksson","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.cgh.2024.08.011","article-title":"Epidemiology of Elderly Onset IBD: A Nationwide Population-Based Cohort Study","volume":"23","author":"Singh","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1093\/ecco-jcc\/jjad025","article-title":"Microbial-Immune Crosstalk in Elderly-Onset Inflammatory Bowel Disease: Unchartered Territory","volume":"17","author":"Meng","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S2468-1253(22)00358-2","article-title":"Management of inflammatory bowel diseases in older adults","volume":"8","author":"Singh","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"jjaf106","DOI":"10.1093\/ecco-jcc\/jjaf106","article-title":"ECCO-ESGAR-ESP-IBUS Guideline on Diagnostics and Monitoring of Patients with Inflammatory Bowel Disease: Part 1","volume":"19","author":"Kucharzik","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"ref_25","first-page":"jjaf125","article-title":"ECCO consensus on management of Inflammatory Bowel Disease in low-and middle-income countries","volume":"20","author":"Hauer","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1053\/j.gastro.2020.12.079","article-title":"Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 1: Live Vaccines","volume":"161","author":"Benchimol","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1053\/j.gastro.2021.04.034","article-title":"Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 2: Inactivated Vaccines","volume":"161","author":"Jones","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"M\u2019Koma, A.E. (2022). Inflammatory Bowel Disease: Clinical Diagnosis and Surgical Treatment-Overview. Medicina, 58.","DOI":"10.3390\/medicina58050567"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.dld.2022.12.024","article-title":"Management of inflammatory bowel disease in the elderly: A review","volume":"55","author":"Sousa","year":"2023","journal-title":"Dig. Liver Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"jjae138","DOI":"10.1093\/ecco-jcc\/jjae138","article-title":"Differences in the Adverse Event Burden of Corticosteroid Use in Inflammatory Bowel Disease as Reported Between Adverse Event Reporting Systems and a Patient Questionnaire","volume":"19","author":"Louis","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11894-025-01005-2","article-title":"Update in Inflammatory Bowel Disease Management in the Elderly","volume":"27","author":"Peerani","year":"2025","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/apt.13139","article-title":"Randomised clinical trial: Deep remission in biologic and immunomodulator na\u00efve patients with Crohn\u2019s disease\u2014A SONIC post hoc analysis","volume":"41","author":"Colombel","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn\u2019s disease","volume":"350","author":"Korzenik","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: The ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Sands","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Holvoet, T., Truyens, M., De Galan, C., Peeters, H., Gismero, F.M., Elorza, A., Torres, P., Vandermeulen, L., Jauregui-Amezaga, A., and Ferreiro-Iglesias, R. (2024). Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort Study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13020365"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/MCG.0000000000001860","article-title":"Safety and Effectiveness of Vedolizumab in Elderly Patients with Inflammatory Bowel Disease: A Systematic Review & Meta-Analysis","volume":"58","author":"Dahiya","year":"2024","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/ecco-jcc\/jjz110","article-title":"IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn\u2019s Disease","volume":"14","author":"Hanauer","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as Induction and Maintenance Therapy for Crohn\u2019s Disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/ibd\/izae174","article-title":"Comparative Safety and Effectiveness of Ustekinumab and Anti-TNF in Elderly Crohn\u2019s Disease Patients","volume":"31","author":"Gebeyehu","year":"2025","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.cgh.2024.07.010","article-title":"Endoscopic, Histologic, and Composite Endpoints in Patients with Ulcerative Colitis Treated with Etrasimod","volume":"23","author":"Magro","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"jjaf074","DOI":"10.1093\/ecco-jcc\/jjaf074","article-title":"Obefazimod in patients with moderate-to-severely active ulcerative colitis: Efficacy and safety analysis from the 96-week open-label maintenance phase 2b study","volume":"19","author":"Vermeire","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1007\/s10620-025-08950-y","article-title":"Mirikizumab in the Treatment of Ulcerative Colitis: Initial Real-World Data in a Population from a Large Tertiary Center","volume":"70","author":"Choi","year":"2025","journal-title":"Dig. Dis. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1053\/j.gastro.2025.02.033","article-title":"Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn\u2019s Disease: Results from the Phase 3 GRAVITI Study","volume":"169","author":"Hart","year":"2025","journal-title":"Gastroenterology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(25)00681-6","article-title":"Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn\u2019s disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials","volume":"406","author":"Panaccione","year":"2025","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"jjaf070","DOI":"10.1093\/ecco-jcc\/jjaf070","article-title":"A multicenter study of the real-world effectiveness and safety of risankizumab in Crohn\u2019s disease","volume":"19","author":"Johnson","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S2468-1253(25)00017-2","article-title":"Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: An interim analysis of the phase 3 U-ACTIVATE long-term extension study","volume":"10","author":"Panaccione","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_52","first-page":"263","article-title":"European Crohn\u2019s and Colitis Organisation Topical Review on IBD in the Elderly","volume":"11","author":"Sturm","year":"2017","journal-title":"J. Crohns Colitis"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2024-334395","article-title":"British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025","volume":"74","author":"Moran","year":"2025","journal-title":"Gut"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1053\/j.gastro.2018.12.009","article-title":"AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis","volume":"156","author":"Ko","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/apt.18406","article-title":"Comparative Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis: A Real-World Multicentre Study in Japan","volume":"61","author":"Akiyama","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1111\/apt.70073","article-title":"Effectiveness and Safety of Upadacitinib Induction Therapy for 223 Patients WithCrohn\u2019s Disease: A GETAID Multicentre Cohort Study","volume":"61","author":"Richard","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2217\/imt-2023-0116","article-title":"The role of filgotinib in ulcerative colitis and Crohn\u2019s disease","volume":"16","author":"Fanizza","year":"2024","journal-title":"Immunotherapy"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"jjad187","DOI":"10.1093\/ecco-jcc\/jjad187","article-title":"Real-world Cohort Study on the Effectiveness and Safety of Filgotinib Use in Ulcerative Colitis","volume":"19","author":"Gros","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.14309\/ajg.0000000000002961","article-title":"Comparative Risk of Serious Infection With Vedolizumab vs Anti-Tumor Necrosis Factor in Inflammatory Bowel Disease: Results from Nationwide Swedish Registers","volume":"119","author":"Karlqvist","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases","volume":"155","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/apt.16060","article-title":"Long-term safety of vedolizumab for inflammatory bowel disease","volume":"52","author":"Loftus","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/MIB.0000000000001074","article-title":"Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn\u2019s Disease: Real-world Experience from a Multicenter Cohort Study","volume":"23","author":"Ma","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.cgh.2021.02.025","article-title":"Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn\u2019s Disease: The IM-UNITI Trial","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/ibd\/izac063","article-title":"Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib","volume":"29","author":"Winthrop","year":"2023","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.4240\/wjgs.v16.i5.1235","article-title":"Surgical treatment of inflammatory bowel disease: From the gastroenterologist\u2019s stand-point","volume":"16","author":"Triantafillidis","year":"2024","journal-title":"World J. Gastrointest. Surg."},{"key":"ref_67","first-page":"22","article-title":"Focal Cancer in Colitis","volume":"37","author":"Lam","year":"2023","journal-title":"Clin. Colon Rectal Surg."},{"key":"ref_68","first-page":"jjae047","article-title":"New surgery and hospital-diagnosed infections in elderly patients with inflammatory bowel disease undergoing surgery\u2014A nationwide cohort study","volume":"18","author":"Garvik","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s10620-023-08250-3","article-title":"Prevalence and Appropriateness of Polypharmacy in Older Adults with Inflammatory Bowel Diseases","volume":"69","author":"Kochar","year":"2024","journal-title":"Dig. Dis. Sci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"323","DOI":"10.14309\/ajg.0000000000002497","article-title":"Older Adult-Onset of Inflammatory Bowel Diseases is Associated with Higher Utilization of Analgesics: A Nationwide Cohort Study","volume":"119","author":"Dalal","year":"2024","journal-title":"Am. J. Gastroenterol."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/2\/59\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T12:55:25Z","timestamp":1769432125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/2\/59"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":70,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["jpm16020059"],"URL":"https:\/\/doi.org\/10.3390\/jpm16020059","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]}}}